
Abstract 4062: A Phase I Study of TST001, a High Affinity Humanized Anti-CLDN18.2 Monoclonal Antibody, in Combination with Capecitabine and Oxaliplatin (CAPOX) as the First Line Treatment of Advanced and Metastatic G/GEJ Cancer


Authors: Jifang Gong¹, Ning Li², Weijian Guo³, Jian Zhang⁴, Hongli Li⁵, Fuyou Zhao⁶, Wei Li⁷, Meili Sun⁸, Zhenzhong Xia⁹, Yu Shen⁹, Jianming Wang⁹, Lingmin Lu⁹, Chuan Qi⁹, Xueming Qian⁹, Michael Shi⁹, Lin Shen¹; ¹Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China; ⁴Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China; ⁴Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China; ⁴Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China; ⁴Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China; ⁴Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China; ⁴Phase I Clinical Trial Center, Shanghai Cancer Center, Shanghai, China; ⁴Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China; ⁴Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China; ⁴Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China; ⁴Phase I Clinical Trial Center, Shanghai Cancer Center, Shanghai, China; ⁴Phase I Clinical Trial Center, Shanghai Cancer Center, Shanghai, China; ⁴Phase I Clinical Trial Center, Shanghai Cancer Center, Shanghai, China; ⁴Phase I Clinical Trial Center, Shanghai Cancer Center, Shanghai, China; ⁴Phase I Clinical Trial Center, Shanghai Cancer Center, Shanghai, China; ⁴Phase I Clinical Trial Center, Sha ⁵Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; ⁶The First Affiliated Hospital, Bengbu, China; ⁸Jinan Central Hospital Affiliated to Shandong University, Jinan, China; ⁹Suzhou Transcenta Therapeutics Co., Ltd

Background

- TST001 is a recombinant humanized IgG1 antibody specifically against human Claudin18.2 (CLDN18.2) with high affinity and enhanced FcR engaging of NK cell
- *In vivo* pharmacology of TST001 in gastric PDX tumor model with CLDN18.2 medium expression: TST001 dose dependently inhibits tumor growth, TST001 exhibits more potent antitumor activity than IMAB362-analog at the same dose (10mg/kg), and more mice reached tumor complete regression. (*Figure 1*)
- TST001 monotherapy dose-escalation study has been completed in China and promising anti-tumor activities were observed in patients with advanced G/GEJC with CLDN18.2 expression who had failed multiple lines of prior therapies.

Figure 1. In Vivo Pharmacology of TST001 in Gastric PDX Tumor Model with CLDN18.2 Medium Expression





Methods

- This cohort aimed to evaluate the safety, tolerability and preliminary efficacy of TST001 in combination with CAPOX as the 1st line treatment of patients with advanced G/GEJ cancer. (ClinicalTrials.gov Identifier: NCT04495296)
- Chinese patients with advanced G/GEJ cancer who had not received prior systemic treatment were enrolled regardless of Claudin18.2 expression in the dose escalation phase following 3+3 design; the safety and efficacy profile was being further evaluated in the dose expansion phase. (*Figure 2*)


Results

- As of April 5, 2022, **14** patients had been dosed with TST001 at 1, 3, 6 or 8 mg/kg plus CAPOX Q3W in the dose escalation phase, and **12** patients at 6 mg/kg Q3W in the expansion phase. (*Table 1*) No subjects experienced dose-limiting toxicities.
- Treatment-emergent adverse events (TEAEs) (*Table 2*) were mostly grade 1-2, including nausea, hypoalbuminemia, anemia, vomiting and AST increased.
- Grade 3 treatment-related AEs included hypertension (11.5%), and nausea, vomiting, anemia, hypoalbuminemia (at 8 mg/kg dose), WBC count decreased, hypocalcemia, ALT increased, AST increased (3.8%, respectively), with no AEs of grade 4 or higher.
- The most common TEAE in TST001 6mg/kg (Table 3) are nausea, hypoalbuminemia, anemia, vomiting and AST increased.
- Among the **9** subjects (*Figure 3*) in the dose-escalation phase with CLDN18.2 unselected who had measurable lesions and had received at least one posttreatment tumor assessments, **5** achieved partial response and **3** achieved stable disease as the best overall response per RECIST1.1.

TST001 -a humanized CLDN18.2 mAb demonstrated manageable safety profile and preliminary clinical efficacy in combination with chemotherapy in Claudin18.2 non-selected 1st line advanced and metastatic G/GEJ Cancer patients.

Age (I Sex, n ECOG Prima St G Gastre Ongoi

Figure 2. Study design of TST001+CAPOX cohort



	1 mg/kg	3 mg/kg	6 mg/kg	8 mg/kg	Overall		
	n=3	n=3	n=15*	n=5	n=26		
(Median, years)	56	51	53	64	55		
n (%)							
Vale	2 (66.7)	1 (33.3)	12 (80.0)	5 (100)	20 (76.9)		
Female	1 (33.3)	2 (66.7)	3 (20.0)	0	6 (23.1)		
G performance Status, n (%)							
)	0	0	2 (13.3)	2 (40.0)	4 (15.4)		
L	3 (100)	3 (100)	13 (86.7)	3 (60.0)	22 (84.6)		
ary tumor, n							
Stomach	3 (100)	2 (66.7)	13 (86.7)	4 (80.0)	22 (84.6)		
GEJ	0	1 (33.3)	2 (13.3)	1 (20.0)	4 (15.4)		
rectomy, n (%)							
None	1 (33.3)	3 (100)	8 (53.3)	5 (100)	17 (65.4)		
Partial	1 (33.3)	0	5 (33.3)	0	6 (23.1)		
Radical or total	1 (33.3)	0	2 (13.3)	0	3 (11.5)		
astatic status at initial diagnosis							
V1	1 (33.3)	3 (100)	5 (33.3)	3 (60.0)	12 (46.2)		
M0 or unknown	2 (66.7)	0	10 (66.7)	2 (40.0)	14 (53.8)		
oing, n (%)	1 (33.3)	2 (66.7)	12 (80.0)	3 (60.0)	18 (69.2)		

Hypoalbu Anaemia Vomiting Aspartate Decreased Hyponatr Alanine a Oedema Fatigue/A Hypocalca Hypertens Periphera Constipat Abdomina Hyperglyc Abdomina Dyspepsia Weight de

Table 3

Nausea


Table 2.

10%	
0%	
-10%	
-20%	
-30%	
-40%	

Conclusion and Future Directions for Research

TEAEs by SOC and PT in the Dose Escalation & Expansion Phase (\geq 20% patients)								
	1 mg/kg n=3	3 mg/kg n=3	6 mg/kg n=15	8 mg/kg n=5	Overall n=26			
with at least one TEAE	3 (100)	3 (100)	15 (100)	5 (100)	26 (100)			
	3 (100)	2 (66.7)	12 (80.0)	5 (100)	22 (84.6)			
uminaemia/hypoproteinemia	2 (66.7)	2 (66.7)	10 (66.7)	4 (80.0)	18 (69.2)			
	3 (100)	3 (100)	8 (53.3)	2 (40.0)	16 (61.5)			
	1 (33.3)	2 (66.7)	7 (46.7)	4 (80.0)	14 (53.8)			
e aminotransferase increased	2 (66.7)	3 (100)	6 (40.0)	0	11 (42.3)			
ed appetite	1 (33.3)	0	6 (40.0)	2 (40.0)	9 (34.6)			
raemia	1 (33.3)	2 (66.7)	4 (26.7)	2 (40.0)	9 (34.6)			
aminotransferase increased	2 (66.7)	3 (100)	4 (26.7)	0	9 (34.6)			
peripheral	1 (33.3)	2 (66.7)	4 (26.7)	0	7 (26.9)			

TEAE in ≥10% patients and ≥G3 TEAEs in 6mg/kg						
Any grade (≥10% patients) n=15 (100.0%)	≥ G3 n=6 (40.0%)					
12 (80.0)	1 (6.7)					
10 (66.7)	0					
8 (53.3)	0					
7 (46.7)	1 (6.7)					
6 (40.0)	0					
6 (40.0)	0					
4 (26.7)	2 (13.3)					
4 (26.7)	1 (6.7)					
4 (26.7)	0					
3 (20.0)	0					
2 (13.3)	1 (6.7)					
2 (13.3)	2 (13.3)					
2 (13.3)	0					
2 (13.3)	0					
2 (13.3)	1 (6.7)					
2 (13.3)	0					
2 (13.3)	0					
2 (13.3)	0					
2 (13.3)	0					
	Any grade (≥10% patients) n=15 (100.0%) 12 (80.0) 10 (66.7) 8 (53.3) 7 (46.7) 6 (40.0) 6 (40.0) 4 (26.7) 4 (26.7) 4 (26.7) 3 (20.0) 2 (13.3) 2 (13.3) 2 (13.3) 2 (13.3) 2 (13.3) 2 (13.3) 2 (13.3) 2 (13.3) 2 (13.3) 2 (13.3)					



• TST001 in combination with CAPOX as the first line treatment of patients with advanced and metastatic G/GEJ cancer is well tolerated and encouraging preliminary anti-tumor activities have been observed.

• The recruitment for the current cohort is ongoing and the safety and efficacy of the combination of TST001+CAPOX as first line treatment for patients with advanced and metastatic G/GEJ cancer will be further evaluated.

